Ancillary Cerebral Blood Flow Testing for Brain Death: Used, But Usefulness (Specificity) Far From Clear*

Ari R. Joffe
DOI: https://doi.org/10.1097/pcc.0000000000003632
2024-12-06
Pediatric Critical Care Medicine
Abstract:Ancillary testing for brain death (BD) when required, according to 2023 recommendations by the American Academy of Neurology (AAN) and the Canadian clinical practice guideline, can be with a nuclear medicine cerebral blood flow (CBF) test ( 1 , 2 ). A lipophilic radionuclide (technetium 99m-hexamethylpropyleneamine oxime [ 99m Tc-HMPAO] or -ethyl cysteinate dimer [ECD]) is preferred as this tracer crosses the blood-brain barrier and uptake by viable brain cells provides a delayed image of brain perfusion. If a lipophilic radionuclide is not available, a lipophobic tracer ( 99m Tc diethylene-triamine-pentaacetate) can be used in children (in the Canadian guideline) and in children and adults (in the AAN guideline) to provide vascular-flow planar imaging ( 1 , 2 ). There is little information on use of CBF ancillary tests in infants under 2 months of age, and the Canadian guideline recommends against using CBF tests at this age ( 3 ). More information on CBF testing in infants is clearly needed.
pediatrics,critical care medicine
What problem does this paper attempt to address?